McAllister K, Goodson N, Warburton L, Rogers G. Spondyloarthritis: diagnosis and management: summary of NICE guidance. Br Med J. 2017;356:j839.
Khmenlinskii N, Regel A, Baraliakos X. The role of imaging in diagnosing axial spondyloarthritis. Front Med. 2018;5:106.
Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25–31.
van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):987–91.
Baraliakos X, Kiltz U, Peters S, Appel H, Dybowski F, Igelmann M, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatol. 2017;56(1):95–102.
Baraliakos X, Kiltz U, Peters S, Appel H, Dybowski F, Igelmann M, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatol. 2017;56(1):95–102.
Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346(18):1349–56.
National Institute of Clinical Excellence. TNF-inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis [Internet]. London. 2016 [cited 2021 May 1]. Available from: https://www.nice.org.uk/guidance/ta383/resources/tnfalpha-inhibitors-for-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis-pdf-2984675907013
National Institute of Clinical Excellence (NICE). Secukinumab for treating non-radiographic axial spondyloarthritis [TA719] [Internet]. London. 2021 [cited 2022 Aug 10]. Available from: https://www.nice.org.uk/guidance/ta719
National Institute of Clinical Excellence (NICE). Ixekizumab for treating axial spondyloarthritis [TA718] [Internet]. London. 2021 [cited 2022 Aug 10]. Available from: https://www.nice.org.uk/guidance/ta718
National Institute of Clinical Excellence (NICE). Upadacitinib for treating active ankylosing spondylitis [ID3848] [Internet]. London. 2022 [cited 2022 Aug 10]. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ta10735
National Institute of Clinical Excellence (NICE). Tofacitinib for treating active ankylosing spondylitis [ID3865] [Internet]. London. 2022 [cited 2022 Aug 10]. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ta10771
Braun J, Brandt J, Listings J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359(9313):1187–93.
Wei JC, Kim T, Kishimoto M, Ogusu N, Jeong H, Kobayashi S, et al. Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial. Ann Rheum Dis. 2021;80(8):1014–21.
UCB Biopharma SRL. A study to evaluate the efficacy and safety of bimekizumab in subjects with active nonradiographic axial spondyloarthritis (BE MOBILE 1) [Internet]. Bethsada. 2019 [cited 2022 Aug 10]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03928704
UCB Biopharma SRL. A study to evaluate the efficacy and safety of bimekizumab in subjects with active ankylosing spondylitis (BE MOBILE 2) [Internet]. Bethsada. 2019 [cited 2022 Aug 10]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03928743
van der Heijde D, Genslet LS, Doedhar A, Baraliakos X, Poddubnyy D, Kivitz A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2020;79(5):595–604.
UCB Biopharma S.P.R.L. A study to evaluate the long-term safety, tolerability and efficacy of bimekizumab in subjects with active axial spondyloarthritis including ankylosing spondylitis and nonradiographic axial spondyloarthritis (BE MOVING) [Internet]. Bethesda. 2020 [cited 2021 Apr 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04436640
Izana Bioscience Ltd. Efficacy and safety of namilumab for moderate-to-severe axial spondyloarthritis (NAMASTE) [Internet]. Bethsada. 2022 [cited 2022 Aug 10]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03622658
van der Heijde D, Baraliakos X, Gensler LS, Maksyowych WP, Tseluyko V, Nadashkevich O, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2378–87.
Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258–70.
Baeten D, Østergaard M, Wei JC, Sieper J, Järvinen P, Tan L, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295–302.
Mease PJ, Chohan S, Fructuoso FJG, Luggen ME, Rahman P, Raychaudhuri SP, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021;80(9):1147–57.
Poddubnyy D, Hermann KA, Callhoff J, Listings J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73(5):817–23.
Braun J, Bollow M, Eggens U, König H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis rheum. 1994;37(7):1039–45.
Bal A, Unlu E, Bahar G, Aydog E, Elsioglu E, Yorgancioglu R. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol. 2007;26(2):211–5.
Liu W, Wu Y, Zhang L, Xue B, Wang YBL, et al. Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis. Int J Clin Exp Med. 2015;8(10):17362–76.
Pedersen SJ, Hetland ML, Sørensen IJ, Ostergaard M, Nielsen HJ, Johansen JS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Clin Rheumatol. 2010;29(11):1301–9.
Tan AL, Marzo-Ortega H, O’Connor P, Fraser A, Emery P, McGonagle D. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis. 2004;63(9):1041–5.
Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis. 2005;64(2):296–8.
Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015;74(6):1051–7.
Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73:1051–7.
Meralshi M, De Marco G, Podgorski M, McGonagle D, Marzo-Ortega H. Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis. Ann Rheum Dis. 2016;75(7):209275.
Baeten DL, Kuchroo VK. How Cytokine Networks Fuel Inflammation: Interleukin-17 and a tale of two autoimmune diseases. Nat Med. 2013;19:824–5.
Marzo-Ortega H. Axial spondyloarthritis: coming of age. Rheumatol. 2020;59(suppl4):iv1-5.
Brown MA, Li Z, Cao KL. Biomarker development for axial spondyloarthritis. Nat Rev Rheumatol. 2020;16(8):448–63.
Gracey E, Vereecke L, McGovern D, Frohling M, Schett G, Danese S, et al. Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol. 2020;16:415–33.
Gracey E, Burssens A, Cambre I, Scheet G, Lories R, McInnes IB, et al. Tendon and ligament mehanical loading in the pathogenesis of inflammatory arthritis. Nat Rev Rheumatol. 2020;16:193–207.
Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, McDermott M. Tumour necrosis factor signalling in health and disease. F1000Res. 2019;8:111.
Garriets V, Goyal A, Khaddour K. Tumour Necrosis Factor Inhibitors. Florida: StatPearls Publishing; 2021. p. 1–14.
Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Parmacology Ther. 2008;117(2):244–79.
Menegatti S, Guillemot V, Latis E, Yahia-Cherbal H, Mittermüller D, Rouilly V, et al. Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo. Ann Rheum Dis. 2021;80(4):475–86.
Bautista-Caro M, Arroyo-Villa I, Castillo-Gallego C, Miguel E, Peiteado D, Puig-Kröger A, et al. Decreased Th17 and Th1 cells in the peripheral blood of patients with early non-radiographic axial spondyloarthritis: a marker of disease activity in HLA-B27+ patients. Rheumatol (Oxford). 2013;52(2):352–62.
Garcia-Montoya L, Emery P. Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials. Expert Opin Investig Drugs. 2021;30(11):1109–24.
Lata M, Hettinghouse AS, Liu C. Targeting tumor necrosis factor receptors in ankylosing spondylitis. Ann N Y Acad Sci. 2019;1442(1):5–16.
Kishimoto M, Ono K, Fukui S, Kawaai S, Deshpande GA, Yoshida K, et al. Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study. RMD Open. 2021;7(3):e001752.
Onna MV, Jurik AG, van der Heijde D, van Tubergen A, Heuft-Dorenbosch L, Landewé R. HLA-B27 and gender independently determine the likelihood of a positive MRI of the sacroiliac joints in patients with early inflammatory back pain: a 2-year MRI follow-up study. Ann Rheum Dis. 2011;70(11):1981–5.
Wong-Baeza I, Rodley A, Shaw J, Hatano H, Rysnik O, McHugh K, et al. KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis. J Immunol. 2013;190(7):3216–24.
Bowness P, Ridley A, Shaw J, Chan AT, Wong-Baeza I, Fleming M, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011;186(4):2672–80.
Gravallese EM, Schett G. Effects of the IL-23–IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol. 2018;1
留言 (0)